1999
DOI: 10.1002/hep.510300329
|View full text |Cite
|
Sign up to set email alerts
|

Chronic hepatitis C: Interferon retreatment of relapsers. A meta-analysis of individual patient data

Abstract: Relapse after interferon (IFN) therapy for chronic hepatitis C virus (HCV) infection occurs in 50% of patients after the initial response. The benefit of retreatment with IFN alone has not been assessed in large controlled studies. To assess the effectiveness and the tolerability of IFN retreatment and to identify the optimal second course regimen, we performed a meta-analysis of individual patient's data on a set of 549 patients (mean age 43.8 years; 12.2 SD, men: 65%) who had an end-of-treatment biochemical … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
20
0

Year Published

2000
2000
2013
2013

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 35 publications
(21 citation statements)
references
References 27 publications
1
20
0
Order By: Relevance
“…79,81,82 In such cases, we observed significant qualitative HCV quasispecies changes after the first course of IFN. 79 The selected HCV variants were not intrinsically resistant to IFN-␣, because they were definitively cleared after the second course of IFN.…”
Section: Figmentioning
confidence: 84%
“…79,81,82 In such cases, we observed significant qualitative HCV quasispecies changes after the first course of IFN. 79 The selected HCV variants were not intrinsically resistant to IFN-␣, because they were definitively cleared after the second course of IFN.…”
Section: Figmentioning
confidence: 84%
“…On the basis of experience gathered from naive patients and from preliminary evidence on retreated patients, 20 we selected as candidate predictors of biochemical and virological SR, age, sex, platelet counts, ALT and γ-glutamyltransferase levels, baseline liver histology, HCV genotype, HCV-RNA levels before retreatment, and amount of IFN received during the first and second cycles. All analyses used a two sided p=0.05 significance level and were conducted with the PROC LOGIS-TIC subroutine in SAS (SAS Institute, Inc., Cary, North Carolina, USA).…”
Section: Discussionmentioning
confidence: 99%
“…Retreatment with the same dose or duration of IFN is rarely effective, but past experience suggests that higher doses, longer duration of therapy, or the addition of more effective agents can induce sustained response in a subset of cases [52][53][54][55]. Although it is not unreasonable to expect that relapsers to IFN monotherapy or standard IFN combination therapy would have a reasonably high chance of response to peginterferon combination therapy, there is currently insufficient data.…”
Section: Ifn Relapsers and Nonrespondersmentioning
confidence: 92%